Influence of immunotropic drugs on immune parameters of patients with dry form of age-related macular degeneration
DOI:
https://doi.org/10.31288/oftalmolzh201516167Keywords:
age-related macular degeneration (AMD), cellular immunity, local immunity, immune preparationsAbstract
Background: AMD is a common cause of irreversible blindness in the elderly and has a high prevalence and a tendency to progressing.
Materials and methods: There were studied disturbance of cellular immunity in 78 patients with the dry form of age-related macular degeneration.
Results: The positive effect of the treatment on the cellular level of systemic immunity. After treatment, the concentration of IL-l?, IL-l?, and NTF-? decreased to 18.3 %, 29.6 % and 36.9 % respectively, while IL-4 levels increased by 63.7 %, the concentration of TGF- ? before the treatment was higher by 57.2 %; after treatment, the concentration of TGF-? decreased by 24 %.
Conclusion: It was established that the use of immunotropic drugs in patients with AMD helped normalize cellular immunity, which was not observed in the control group as well as to reduce the content and IgA TGF-?, normalization of the normal ratio of pro- and anti-inflammatory cytokines in the lachrymal fluid.
References
1.Astakhov YuS, Lisochkina AB, Shadrichev FE. Age-related macular degeneration. Ophthalmology; national guidance. Avetisov SE, Moshetova LK, Neroev VV, Takhchidi KhP. Editors. M.:GEOTAR-Media; 2008.
2.Belenichev IF, Cherny VI, Kolesnik YuM, Pavlov SV. Rational neuroprotection. 2009. 262 p.
3.Boiko EV, Zhuravleva LV. Experience of using «Lutein forte» in the treatment of «dry» form of age-related macular degeneration. Klinicheskaia oftalmologiia. 2007;8(2).
4.Vervelskaia VM, Lebenkova OA. Features of frequency-critical and frequency-contrast sensitivity of the eye to the colors in optic atrophy. Akyualnyie voprosy sotsialnoi oftalmologii. 1988;2:43-47. In Russian.
5.Golubtsov KV, Kheilo TS, Shigina NA, Trunov VG, Aidu EA-I, Bykova TA, et al. The flickering light in the diagnosis and treatment of pathological processes of the human visual system. Informatsionnyie protsessy. 3(2):114-22. In Russian.
6.Granstrem OK et al. Cortexin: neuroprotection at the molecular level. Neiroimmunologiia. 2010;8(1-2):34-40. In Russian.
7.Egorova TE. Antioxidants in the treatment and prevention of the dry form of age-related macular degeneration. Literature review. Klin. Oftalmologiia. 2010;11(2):69-71. In Russian.
8.Zhuravleva LV, Churilova IV. The effectiveness of antioxidants in complex treatment of patients with age macular degeneration. Proceedings of VII Congress of ophthalmologists of Russia. M.;2000. 311. In Russian.
9.Libman ES, Shakhova EV. Blindness, visual impairment and visual disability in the Russian Federation. Proceedings of Russian interregional symposium. Ufa, 2003. 38-42. In Russian.
10.Libman ES, Shakhova EV. Blindness and disability due to pathology of the vision in Russia. Vestn Oftalmol. 2006;1:35-7. In Russian.
11.Maichuk YuF. The principles of the WHO global initiative to eliminate avoidable blindness. Their possible use in the Russian Federation. Okulist. 2003;44(4):5-8. In Russian.
12.Mukhina MA, Sotnikova EV, Kutepova OM. Social significance and urgency of treatment of age-related macular degeneration.. Proceedings of VII Congress of ophthalmologists of Russia. M.; 2000. 220. In Russian.
13.Pasyechnikova NV, Korol AR. Clinical classification and tactics of management of patients with age related macular degeneration. Oftalmol Zh. 2010;2:38-41. In Russian. https://doi.org/10.31288/oftalmolzh201023841
14.Ponomarchuk VS, Ivanov VA, Fiadoer S. Method and device for the differential diagnosis of pathological conditions of the retina. Oftalmol Zh. 1990;8:451-5. In Russian.
15.Tovkach VI. Photostress by conventional electric ophthalmoscope in the diagnosis of eye diseases. Voien. Med. Zhurnal. 1977;8:40-4. In Russian.
16.Frolov VM, Gaidash IS, Peresadin NA. Monoclonal antibodies in the study of cellular immunity. Laboratornoie delo. 1989;6:71-2. In Russian.
17.С De Palma et al. Endothelial nitric oxide synthase activation by tumor necrosis factor-a. Arterisclerosis, Throbbosis and vase. Biol. 2006;1:99-106. https://doi.org/10.1161/01.ATV.0000194074.59584.42
18.Friedman E et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology. 1995; 102(4): 640- 6. https://doi.org/10.1016/S0161-6420(95)30974-8
19.Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am. J. Ophthalmol. 2000;130(5):658-63. https://doi.org/10.1016/S0002-9394(00)00643-7
20.Klein R, Klein BE, Knudtson MD et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006;113:373-80. https://doi.org/10.1016/j.ophtha.2005.12.013
21.Pierce EA. Prophylactic treatment of drusen in AMD. Bio Essay. 2001; 23: 605-18.https://doi.org/10.1002/bies.1086
22.Resnikoff S et al. Bulletin of the World Health Organization. 2004;82(11):844-51.
23.Williamson TH, Harris A. Color Doppler ultrasound imaging of the eye and orbit. Surv. Ophthalmol.1996; 40:255(203.) https://doi.org/10.1016/S0039-6257(96)82001-7
24.Wu G, Weiter JJ, Santos S et al. The macular photostress test indiabetic retinopathy and age-related macular degeneration. Arch.Ophthalmol. 1990;108:1556-8. https://doi.org/10.1001/archopht.1990.01070130058030
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 А. М. Петруня, О. А. Евсюкова
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
